Annular lichen planus 
Atrophic lichen planus
Bullous lichen planus (vesiculobullous lichen planus)
Erosive lichen planus
Erythema dyschromicum perstans (ashy dermatosis, dermatosis cinecienta)
Giant cell lichenoid dermatitis
Hepatitis-associated lichen planus
Hypertrophic lichen planus (lichen planus verrucosus)
Idiopathic eruptive macular pigmentation
Inverse lichen planus
Keratosis lichenoides chronica (Nékams disease)
Kraurosis vulvae
Lichen nitidus
Lichen planus actinicus (actinic lichen niditus, actinic lichen planus, lichen planus atrophicus annularis, lichen planus subtropicus, lichen planus tropicus, lichenoid melanodermatitis, lichenoid melanodermatosis, summertime actinic lichenoid eruption)
Lichen planus pemphigoides
Lichen planus pigmentosus
Lichen planus–lichen sclerosus overlap syndrome
Lichen ruber moniliformis
Lichen sclerosus (lichen sclerosus et atrophicus)
Lichen striatus (Blaschko linear acquired inflammatory skin eruption, linear lichenoid dermatosis)
Lichen verrucosus et reticularis
Lichenoid trikeratosis
Lichenoid dermatitis
Lichenoid reaction of graft-versus-host disease
Linear lichen planus
Mucosal lichen planus
Peno-gingival syndrome
Ulcerative lichen planus
Vulvovaginal gingival syndrome
Vulvovaginal lichen planus

Lymphoid-related
Lymphoid-related cutaneous conditions are a group of disorders characterized by collections of lymphocyte cells within the skin.
In regard to the latter, estradiol valerate is available in combination with a progestin as a combined estradiol-containing oral contraceptive (with dienogest) and as a combined injectable contraceptive. Along with estradiol cypionate, estradiol undecylate, and estradiol benzoate, estradiol valerate is used as a form of high-dose estrogen therapy in feminizing hormone therapy for transgender women. It is also used as a form of high-dose estrogen therapy in the treatment of prostate cancer in men. Low-dose oral estradiol valerate (2–6 mg/day) has been used in the treatment of breast cancer in women who were previously treated with and benefited from but acquired resistance to aromatase inhibitors as well. Injectable estradiol valerate has been used to suppress sex drive in sex offenders.In the United States, the approved indications of estradiol valerate injections include the treatment of moderate to severe hot flashes and vaginal atrophy associated with menopause in women, the treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure in women, and the palliative treatment of advanced prostate cancer in men. Elsewhere in the world, oral estradiol valerate is similarly approved for the treatment of symptoms associated with menopause or hypoestrogenism due to castration in women. Such symptoms may include hot flashes, outbreaks of sweat, sleep disturbances, depressive moods, irritability, headaches, and dizziness.Estradiol valerate by intramuscular injection is usually used at a dosage of 10 to 20 mg every 4 weeks in the treatment of menopausal symptoms and hypoestrogenism due to hypogonadism, castration, or primary ovarian failure in women.